The FDA on July 13, 2018 approved XTANDI® for patients with Castration-Resistant Prostate Cancer (CRPC). This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. XTANDI® was previously approved for the treatment of patients with metastatic CRPC. XTANDI® is a product of Astellas Pharma US, Inc.
Bottom Ad
Advertisement
Subscribe
